These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 8647788)

  • 21. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
    Bailly D
    Presse Med; 2006 Oct; 35(10 Pt 2):1507-15. PubMed ID: 17028514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
    Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
    J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical overview of serotonin reuptake inhibitors.
    Rickels K; Schweizer E
    J Clin Psychiatry; 1990 Dec; 51 Suppl B():9-12. PubMed ID: 2147922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidepressant response in late-life depression.
    Roose SP; Suthers KM
    J Clin Psychiatry; 1998; 59 Suppl 10():4-8. PubMed ID: 9720475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
    Tulloch IF; Johnson AM
    J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory.
    Zajecka J; Mitchell S; Fawcett J
    Psychopharmacol Bull; 1997; 33(4):755-60. PubMed ID: 9493488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
    Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
    Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.
    Thase ME; Blomgren SL; Birkett MA; Apter JT; Tepner RG
    J Clin Psychiatry; 1997 Jan; 58(1):16-21. PubMed ID: 9055832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity of SSRI response.
    Salzman C
    Harv Rev Psychiatry; 1996; 4(4):215-7. PubMed ID: 9384996
    [No Abstract]   [Full Text] [Related]  

  • 32. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?
    Zarate CA; Kando JC; Tohen M; Weiss MK; Cole JO
    J Clin Psychiatry; 1996 Feb; 57(2):67-71. PubMed ID: 8591971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses.
    Taylor D
    Br J Psychiatry; 1995 Nov; 167(5):575-80. PubMed ID: 8564311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective serotonin-reuptake inhibitors: an update.
    Masand PS; Gupta S
    Harv Rev Psychiatry; 1999; 7(2):69-84. PubMed ID: 10471245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups.
    Philipp M; Tiller JW; Baier D; Kohnen R
    Eur Neuropsychopharmacol; 2000 Sep; 10(5):305-14. PubMed ID: 10974600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
    Flament MF; Bisserbe JC
    J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sertraline: a review of its use in the management of major depressive disorder in elderly patients.
    Muijsers RB; Plosker GL; Noble S
    Drugs Aging; 2002; 19(5):377-92. PubMed ID: 12093324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.
    Prescrire Int; 2004 Oct; 13(73):163-5. PubMed ID: 15499694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychopharmacologic treatment of adolescent depression.
    Lynch A; Glod CA; Fitzgerald F
    Arch Psychiatr Nurs; 2001 Feb; 15(1):41-7. PubMed ID: 11172238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.